Managing side effects in adjuvant endocrine therapy for breast cancer

References

• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet Lond Engl. 2005 May 14;365(9472):1687–1717.
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. The Lancet. 2005 Jan;365(9453):60–62.
   PubMed Web of Science ®Google Scholar
• Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29;353(26):2747–2757.
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004 Mar 11;350(11):1081–1092.
   PubMed Web of Science ®Google Scholar
• Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. The Lancet. 2005 Aug;366(9484):455–462.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003 Nov 6;349(19):1793–1802.
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet. 2013 Mar;381(9869):805–816.
   PubMed Web of Science ®Google Scholar
• Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013;31(15_suppl):5. mai.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016 Jul 21;375(3):209–219.
   PubMed Web of Science ®Google Scholar
• Mamounas E, Bandos H, Lembersky B, et al. Abstract S1-05: a randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): results from NRG Oncology/NSABP B-42. Cancer Res. 2017 Feb 15;77(4Supplement):S1-05-S1-05.
   Google Scholar
• Tjan-Heijnen V, Van Hellemond I, Peer P, et al. Abstract S1-03: first results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer. Cancer Res. 2017 Feb 15;77(4Supplement):S1-03-S1-03.
   Google Scholar
• Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006–05). J Natl Cancer Inst. 2018 1;110(1):Jan.
   Google Scholar
• Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10;371(2):107–118.
   PubMed Web of Science ®Google Scholar
• Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001;344(4):276–285.
   PubMed Web of Science ®Google Scholar
• Brandenberger AW, Tee MK, Lee JY, et al. Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus. J Clin Endocrinol Metab. 1997 Oct;82(10):3509–3512.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Rowland JH, Desmond K, et al. Life after breast cancer: understanding women’s health-related quality of life and sexual functioning. J Clin Oncol. 1998 Feb;16(2):501–514.
   PubMed Web of Science ®Google Scholar
• Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol. 1995 Nov;13(11):2737–2744.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Petersen L, Bower JE, et al. Impact of adjuvant endocrine therapy on quality of life and symptoms: observational data over 12 months from the mind-body study. J Clin Oncol. 2016 Mar 10;34(8):816–824.
   PubMed Web of Science ®Google Scholar
• Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015 Jul;16(7):848–858.
   PubMed Web of Science ®Google Scholar
• Ribi K, Luo W, Bernhard J, et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol Off J Am Soc Clin Oncol. 2016 May 10;34(14):1601–1610.
   PubMed Web of Science ®Google Scholar
• McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008 Dec 2;99(11):1763–1768.
   PubMed Web of Science ®Google Scholar
• Makubate B, Donnan PT, Dewar JA, et al. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013 Apr 16;108(7):1515–1524.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003 Feb 15;21(4):602–606.
   PubMed Web of Science ®Google Scholar
• Barron TI, Connolly R, Bennett K, et al. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007 Mar 1;109(5):832–839.
   PubMed Web of Science ®Google Scholar
• Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008 Feb;26(4):556–562.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Greendale GA, Petersen L, et al. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst. 2000 Jul 5;92(13):1054–1064.
   PubMedGoogle Scholar
• Avis NE, Smith KW, McGraw S, et al. Assessing quality of life in adult cancer survivors (QLACS). Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2005 May;14(4):1007–1023.
   PubMed Web of Science ®Google Scholar
• Chopra I, Kamal KM. A systematic review of quality of life instruments in long-term breast cancer survivors. Health Qual Life Outcomes. 2012;10(1):14.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Earle CC, Goodwin PJ. Journal of clinical oncology update on progress in cancer survivorship care and research. J Clin Oncol Off J Am Soc Clin Oncol. 2012 Oct 20;30(30):3655–3656.
   PubMed Web of Science ®Google Scholar
• Denlinger CS, Sanft T, Baker KS, et al. Survivorship, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2017 Sep;15(9):1140–1163.
   PubMed Web of Science ®Google Scholar
• Runowicz CD, Leach CR, Henry NL, et al. American cancer society/American society of clinical oncology breast cancer survivorship care guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2016 Feb 20;34(6):611–635.
   PubMed Web of Science ®Google Scholar
• Edge SB, Sobin LH, Page DL, et al. Re: colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2005 Apr 6;97(6):463–4; author reply 464–5.
   PubMedGoogle Scholar
• Holmberg L, Iversen O-E, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. JNCI J Natl Cancer Inst. 2008 Apr 2;100(7):475–482.
   Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women’s health initiative randomized trial. JAMA. 2003 Jun 25;289(24):3243.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994 Aug 11;331(6):347–352.
   PubMed Web of Science ®Google Scholar
• Goodwin JW, Green SJ, Moinpour CM, et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: southwest oncology group study 9626. J Clin Oncol. 2008 Apr;26(10):1650–1656.
   PubMed Web of Science ®Google Scholar
• Bertelli G, Venturini M, Del Mastro L, et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol Off J Eur Soc Med Oncol. 2002 Jun;13(6):883–888.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: north central cancer treatment group trial N99C7. J Clin Oncol. 2006 Mar 20;24(9):1409–1414.
   PubMed Web of Science ®Google Scholar
• Muggia FM, Cassieth PA, Ochoa M, et al. Treatment of breast cancer with medroxyprogesterone acetate. Ann Intern Med. 1968 Feb;68(2):328–337.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Buzdar AU, Frye D, et al. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1985;5(3):321–326.
   PubMed Web of Science ®Google Scholar
• Eden J. Progestins and breast cancer. Am J Obstet Gynecol. 2003 May;188(5):1123–1131.
   PubMed Web of Science ®Google Scholar
• Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995 Jun 15;332(24):1589–1593.
   PubMed Web of Science ®Google Scholar
• Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016 Oct 12;10:CD008536.
   PubMedGoogle Scholar
• Kenemans P, Bundred NJ, Foidart J-M, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 2009 Feb;10(2):135–146.
   PubMed Web of Science ®Google Scholar
• Bundred NJ, Kenemans P, Yip CH, et al. Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Res BCR. 2012 Jan 17;14(1):R13.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. The Lancet. 2000 Dec;356(9247):2059–2063.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol. 2009 Jun 10;27(17):2831–2837.
   PubMed Web of Science ®Google Scholar
• Johns C, Seav SM, Dominick SA, et al. Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Breast Cancer Res Treat. 2016 Apr;156(3):415–426.
   PubMed Web of Science ®Google Scholar
• Shams T, Firwana B, Habib F, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med. 2014 Jan;29(1):204–213.
   PubMed Web of Science ®Google Scholar
• Donneyong MM, Bykov K, Bosco-Levy P, et al. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ. 2016 Sep;30(354):i5014.
   Google Scholar
• Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010 Feb;8(340):c693.
   Google Scholar
• Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003 Dec 3;95(23):1758–1764.
   PubMed Web of Science ®Google Scholar
• Haque R, Shi J, Schottinger JE, et al. Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors. J Natl Cancer Inst. 2016;108:3.
   Google Scholar
• Azoulay L, Dell’Aniello S, Huiart L, et al. Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat. 2011 Apr;126(3):695–703.
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. The Lancet. 2005 Sep;366(9488):818–824.
   PubMed Web of Science ®Google Scholar
• Reddy SY, Warner H, Guttuso T, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol. 2006 Jul;108(1):41–48.
   PubMedGoogle Scholar
• Loprinzi CL, Qin R, Balcueva EP, et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol Off J Am Soc Clin Oncol. 2010 Feb 1;28(4):641–647.
   PubMed Web of Science ®Google Scholar
• Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 2010 Dec 10;28(35):5147–5152.
   PubMed Web of Science ®Google Scholar
• Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006 May 3;295(17):2057.
   PubMed Web of Science ®Google Scholar
• Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. 2017 May;389(10081):1809–1820.
   PubMed Web of Science ®Google Scholar
• Bardia A, Thompson S, Atherton PJ, et al. Pilot Evaluation of aprepitant for the treatment of hot flashes. Support Cancer Ther. 2006 Jul;3(4):240–246.
   PubMedGoogle Scholar
• Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews [Internet] Chichester, UK: John Wiley & Sons, Ltd; 2010 cited 2017 Jun 20. Available from DOI:10.1002/14651858.CD004923.pub2.
   Google Scholar
• Reed SD, Guthrie KA, Newton KM, et al. Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements. Am J Obstet Gynecol. 2014 Mar;210(3):244.e1–244.e11.
   Web of Science ®Google Scholar
• Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG trial N01CC1. J Clin Oncol Off J Am Soc Clin Oncol. 2006 Jun 20;24(18):2836–2841.
   PubMed Web of Science ®Google Scholar
• Park H, Qin R, Smith TJ, et al. North central cancer treatment group N10C2 (alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause. 2015 Jun;22(6):627–632.
   PubMed Web of Science ®Google Scholar
• Pruthi S, Qin R, Terstreip SA, et al. A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: north central cancer treatment group N08C7. Menopause N Y N. 2012 Jan;19(1):48–53.
   PubMed Web of Science ®Google Scholar
• Kadakia KC, Loprinzi CL, Atherton PJ, et al. Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2016 Mar;24(3):1061–1069.
   PubMed Web of Science ®Google Scholar
• Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol Off J Am Soc Clin Oncol. 1998 Feb;16(2):495–500.
   PubMed Web of Science ®Google Scholar
• Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):309–318.
   PubMed Web of Science ®Google Scholar
• Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol. 2008 Nov;26(31):5022–5026.
   PubMed Web of Science ®Google Scholar
• Dodin S, Blanchet C, Marc I, et al. Acupuncture for menopausal hot flushes. In: The Cochrane Collaboration, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2013 cited 2017 Jun 20. Available from doi:10.1002/14651858.CD007410.pub2
   Google Scholar
• Mao JJ, Bowman MA, Xie SX, et al. Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2015 Nov 1;33(31):3615–3620.
   PubMed Web of Science ®Google Scholar
• Lesi G, Razzini G, Musti MA, et al. Acupuncture As an integrative approach for the treatment of hot flashes in women with breast cancer: A prospective multicenter randomized controlled trial (AcCliMaT). J Clin Oncol Off J Am Soc Clin Oncol. 2016 May 20;34(15):1795–1802.
   PubMed Web of Science ®Google Scholar
• Sternfeld B, Guthrie KA, Ensrud KE, et al. Efficacy of exercise for menopausal symptoms: a randomized controlled trial. Menopause. 2014 Apr; 21 (4): 330-8.
   Web of Science ®Google Scholar
• Newton KM, Reed SD, Guthrie KA, et al. Efficacy of yoga for vasomotor symptoms: a randomized controlled trial. Menopause. 2014 Apr; 21(04):339-346.
   Web of Science ®Google Scholar
• Daley A, Stokes-Lampard H, Thomas A, et al., Exercise for vasomotor menopausal symptoms. The Cochrane Collaboration, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd: 2014 cited 2017 Jun 20. Available from doi:10.1002/14651858.CD006108.pub4
   Google Scholar
• Su HI, Sammel MD, Springer E, et al. Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Res Treat. 2010 Nov;124(1):205–211.
   PubMed Web of Science ®Google Scholar
• Caan BJ, Emond JA, Su HI, et al. Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors. J Clin Oncol. 2012 May;30(13):1492–1497.
   PubMed Web of Science ®Google Scholar
• Walega DR, Rubin LH, Banuvar S, et al. Effects of stellate ganglion block on vasomotor symptoms: findings from a randomized controlled clinical trial in postmenopausal women. Menopause. 2014 Aug;21(8):807–814.
   PubMed Web of Science ®Google Scholar
• Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012 Mar 20;30(9):936–942.
   PubMed Web of Science ®Google Scholar
• Briot K, Tubiana-Hulin M, Bastit L, et al. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat. 2010 Feb;120(1):127–134.
   PubMed Web of Science ®Google Scholar
• Henry N, Unger J, Schott A, et al. Abstract S5-06: randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG S1202). Cancer Res. 2017 Feb 15;77(4Supplement):S5-06-S5-06.
   PubMedGoogle Scholar
• Khan QJ, Reddy PS, Kimler BF, et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat. 2010 Jan;119(1):111–118.
   PubMed Web of Science ®Google Scholar
• Singh S, Cuzick J, Mesher D, et al. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. Breast Cancer Res Treat. 2012 Apr;132(2):625–629.
   PubMed Web of Science ®Google Scholar
• Greenlee H, Crew KD, Shao T, et al. Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Support Care Cancer. 2013 Apr;21(4):1077–1087.
   PubMed Web of Science ®Google Scholar
• Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol. 2013 Jun 1;24(6):1443–1449.
   PubMed Web of Science ®Google Scholar
• Kubo M, Onishi H, Kuroki S, et al. Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res. 2012 Jun;32(6):2331–2336.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Unger JM, Crew KD, et al. Randomized multicenter placebo-controlled trial of omega-3 fatty acids for the control of aromatase inhibitor?induced musculoskeletal pain: SWOG S0927. J Clin Oncol. 2015 Jun 10;33(17):1910–1917.
   PubMed Web of Science ®Google Scholar
• Crew KD, Capodice JL, Greenlee H, et al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor?associated joint symptoms in women with early-stage breast cancer. J Clin Oncol. 2010 Mar;28(7):1154–1160.
   PubMed Web of Science ®Google Scholar
• Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor–induced arthralgia in breast cancer survivors. J Clin Oncol. 2015 Apr;33(10):1104–1111.
   PubMed Web of Science ®Google Scholar
• Melisko ME, Goldman ME, Hwang J, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 2017 Mar 1;3(3):313.
   PubMed Web of Science ®Google Scholar
• Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric J Int Menopause Soc. 2003 Mar;6(1):45–52.
   PubMed Web of Science ®Google Scholar
• Le Ray I, Dell’Aniello S, Bonnetain F, et al. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case–control study. Breast Cancer Res Treat. 2012 Sep;135(2):603–609.
   PubMed Web of Science ®Google Scholar
• Kendall A. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006 Apr 1;17(4):584–587.
   PubMed Web of Science ®Google Scholar
• Biglia N, Peano E, Sgandurra P, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2010 Jun;26(6):404–412.
   PubMed Web of Science ®Google Scholar
• Wills S, Ravipati A, Venuturumilli P, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract. 2012 May;8(3):144–148.
   PubMedGoogle Scholar
• Donders G, Neven P, Moegele M, et al. Ultra-low-dose estriol and lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat. 2014 Jun;145(2):371–379.
   PubMed Web of Science ®Google Scholar
• Pfeiler G, Glatz C, Königsberg R, et al. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric J Int Menopause Soc. 2011 Jun;14(3):339–344.
   PubMed Web of Science ®Google Scholar
• Barton DL, Sloan JA, Shuster LT, et al. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (alliance). Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2018 Feb; 26 (2):643-650.
   Google Scholar
• Moegele M, Buchholz S, Seitz S, et al. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet. 2012 May;285(5):1397–1402.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 1997 Mar;15(3):969–973.
   PubMed Web of Science ®Google Scholar
• Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol Off J Am Soc Clin Oncol. 2015 Oct 20;33(30):3394–3400.
   PubMed Web of Science ®Google Scholar
• Biglia N, Bounous VE, Sgro LG, et al. Genitourinary syndrome of menopause in breast cancer survivors: are we facing new and safe hopes? Clin Breast Cancer. 2015 Dec;15(6):413–420.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA. Ospemifene study group. ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause N Y N. 2013 Jun;20(6):623–630.
   PubMed Web of Science ®Google Scholar
• Simon JA, Vh L, Radovich C, et al. Ospemifene study group. one-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause N Y N. 2013 Apr;20(4):418–427.
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Komi JO. Ospemifene study group. ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause N Y N. 2010 Jun;17(3):480–486.
   PubMed Web of Science ®Google Scholar
• Goetsch MF, Lim JY, Caughey AB. Locating pain in breast cancer survivors experiencing dyspareunia: a randomized controlled trial. Obstet Gynecol. 2014 Jun;123(6):1231–1236.
   PubMed Web of Science ®Google Scholar
• Biglia N, Bounous VE, Sgro LG, et al. Treatment of climacteric symptoms in survivors of gynaecological cancer. Maturitas. 2015 Nov;82(3):296–298.
   PubMed Web of Science ®Google Scholar
• Zerbinati N, Serati M, Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci. 2015 Jan;30(1):429–436.
   PubMed Web of Science ®Google Scholar